PDCD1 and non-small cell lung carcinoma: A meta-analysis assessing ICIs in stage III NSCLC patients revealed a significantly greater incidence of grade 2 pneumonia with anti-PD-1 therapy than with anti-PD-L1 therapy (22.7% vs 14.9%; OR=2.10, P<0.01) (21).